Showing results (131-140 of 146) with videos related to
Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 22, 2011
Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplificationJun Guo, Lu Si, Yan Kong, et al.Theranostics|May 13, 2022
Erratum: MicroRNA-23a-3p Inhibits Mucosal Melanoma Growth and Progression through Targeting Adenylate Cyclase 1 and Attenuating cAMP and MAPK Pathways: ErratumMeng Ma, Jie Dai, Huan Tang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2019
Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G<sub>4</sub> Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB TrialXinan Sheng, Xieqiao Yan, Zhihong Chi, et al.The British Journal of Dermatology|January 18, 2022
Prognostic value of ulceration varies across Breslow thicknesses and clinical stages in acral melanoma: a retrospective studyXiaoting Wei, Di Wu, Yu Chen, et al.Journal of Hematology & Oncology|January 16, 2019
Safety and clinical activity with an anti-PD-1 antibody JS001 in advanced melanoma or urologic cancer patientsBixia Tang, Xieqiao Yan, Xinan Sheng, et al.Journal for Immunotherapy of Cancer|January 2, 2023
Molecular underpinnings of exceptional response in primary malignant melanoma of the esophagus to anti-PD-1 monotherapyJie Dai, Xue Bai, Xuan Gao, et al.Annals of Surgical Oncology|April 10, 2022
An Evidence-Based Staging System for Mucosal Melanoma: A ProposalChuanLiang Cui, Bin Lian, XiaoShi Zhang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 4, 2019
Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous MelanomaJiayi Yu, Junya Yan, Qian Guo, et al.JAMA Oncology|June 1, 2023
Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical TrialLili Mao, Bin Lian, Caili Li, et al.Journal of the American Academy of Dermatology|September 8, 2022
Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysisXiaoting Wei, Yu Chen, Hong Yao, et al.Pageof 15